NovoCure Priced, Nasdaq: NVCR

Markets a wearable electric field device for treating glioblastoma brain cancer.

Industry: Health Care

Latest Trade: $19.28 +0.03 (+0.1%)

First Day Return: -16.9%

Return from IPO: -12.5%

Industry: Health Care

We are a commercial-stage oncology company developing a novel, proprietary therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on key molecules inside cancer cells, disrupting the basic machinery necessary for normal cell division, leading to cancer cell death. Physicians have typically treated patients with solid tumors using one or a combination of three principal treatment modalities—surgery, radiation and pharmacological therapies. Despite meaningful advancements in each of these modalities, a significant unmet need to improve survival and quality of life remains. We believe we will establish TTFields as a new treatment modality for a variety of solid tumors that increases survival without significantly increasing side effects when used in combination with other cancer treatment modalities.
more less
IPO News for NovoCure
more
IPO Data
IPO File Date 08/31/2015
Offer Price $22.00
Price Range $23.00 - $24.00
Offer Shares (mm) 7.5
Deal Size ($mm) $165
IPO Data
IPO Date 10/01/2015
Offer Price $22.00
Price Range $23.00 - $24.00
Offer Shares (mm) 7.5
Deal Size ($mm) $165
Underwriters
more
Company Data
Headquarters St Helier, Jersey
Founded 2000
Employees 258
Website www.novocure.com